Kardigan is preparing an initial public offering on the Nasdaq to raise capital to support development of three late‑stage cardiovascular drugs.
The company plans to list on the Nasdaq Global Market under the ticker symbol “KARD”.
The proceeds will primarily back clinical development of three late‑stage therapies:
danicamtiv (for genetic dilated cardiomyopathy), ataciguat (for calcific aortic valve stenosis), and tonlamarsen (for acute severe hypertension).
Kardigan filed its IPO proposal with the SEC on May 26, 2026, making it one of several cardiology‑focused biotechs eyeing Nasdaq this year.
The company has already raised about $570 million in private funding, including a $254 million Series B in October 2025, to advance these three programs.
Sources:
Kardigan targets IPO to support cardiology pipeline progression
Sell or Invest in Kardigan Stock Pre-IPO - Nasdaq Private Market
Kardigan | Cardiovascular Drug Development for Heart Health
Biotech veteran Tassos Gianakakos, Kardigan knit IPO candidate
Kardigan, Inc (KARD) files for proposed Nasdaq IPO
Cardio drugmaker Kardigan plans to go public | BioPharma Dive
Kardigan itching for IPO to fund late-stage cardio pipeline
Cardiovascular drug developer Kardigan files for US IPO - Mix 92.9
Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio ...
Heart drug developer Kardigan files for US IPO - WHBL
Cardiovascular drug developer Kardigan files for US IPO - bars
Cardiovascular drug developer Kardigan files for US IPO - KELO-AM
Cardiovascular drug developer Kardigan files for US IPO - WIXX